The effect of dexmedetomidine on the sedation during the radiofrequency ablation of hepatic neoplasm

Sedation and respiratory effects of dexmedetomidine-remifentanil compared with propofol -remifentanil during percutaneous radiofrequency ablation of hepatic tumor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003229

Enrollment

Registered

2018-09-28

Start date

2015-11-16

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The patients were ramdomly assigned to dexmedetomidine-remifentanil group and propofol-remifentanil group, we examed baseline vital signs before the procedure. 1. Dexmedetomidine group: dexmede

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who undergoing a radiofrequency ablation therapy for hepatic neoplasm 2. American Society of Anesthesiologist physical class 1, 2, 3 3. Platelet count > 50,000/µL

Exclusion criteria

Exclusion criteria: 1. Bradycardia (heart rate <50) 2. Second or Third degree atrioventricular block 3. Hypersensitivity of propofol, dexmedetomidine, remifentanil 4. End stage cardiac / renal / hepatic disease 5. Abuse history of opioid or propofol

Design outcomes

Primary

Measure	Time frame
respiratory tidal volume of patient	—

Secondary

Measure	Time frame
vital signs(blood pressure, heart rate, respiration rate, oxygen saturation);level of sedation;satisfaction rate of patient;satisfactio rate of operator	—

Countries

Korea, Republic of

Contacts

Public ContactJi Won Choi

Samsung Medical Center

jiwon0715.choi@samsung.com+82-2-3410-0730

Outcome results